Evidence map›Paper›PMID 37865688›Full record

ArticleBritish journal of cancer2023

Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.

Jessica L Petrick, Charlotte E Joslin, Courtney E Johnson, T Fabian Camacho, Lauren C Peres, Elisa V Bandera, Mollie E Barnard, Alicia Beeghly, Traci N Bethea, Lauren F Dempsey and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 1 country.

Jessica L Petrick *Slone Epidemiology Center at Boston University, Boston, MA, USA. jpetrick@bu.edu.ORCID 0000-0001-6580-450X
Charlotte E Joslin *Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago School of Medicine, Chicago, IL, USA.
Courtney E JohnsonDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
T Fabian CamachoDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
Lauren C PeresDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-6620-8600
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID 0000-0002-8789-2755
Mollie E BarnardSlone Epidemiology Center at Boston University, Boston, MA, USA.ORCID 0000-0002-4843-4655
Alicia BeeghlyDepartment of Medicine, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Traci N BetheaOffice of Minority Health and Health Disparities Research, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Campus, Washington, DC, USA.ORCID 0000-0003-3205-2078
Lauren F DempseyDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Kristin GuertinDepartment of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA.
Holly R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Patricia G MoormanDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA.
Evan R MyersDepartment of Family Medicine and Community Health, Duke University Medical Center, Durham, NC, USA.
Heather M Ochs-BalcomDepartment of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA.ORCID 0000-0003-1255-7714
Will RosenowDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
V Wendy SetiawanUniversity of Southern California Norris Comprehensive Cancer Center and Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Anna H WuUniversity of Southern California Norris Comprehensive Cancer Center and Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Joellen M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID 0000-0002-0990-9339
Lynn RosenbergSlone Epidemiology Center at Boston University, Boston, MA, USA.
Boston University · USEmory University · USDuke Medical Center · USUniversity of Southern California · USUniversity of Virginia · USGeorgetown University · USMoffitt Cancer Center · USRutgers, The State University of New Jersey · USUniversity at Buffalo, State University of New York · USUniversity of Connecticut · USUniversity of Illinois Chicago · USUniversity of Washington · USVanderbilt University Medical Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
A Follow-up Study for Causes of Cancer in Black WomenU01CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Kimberly A. Bertrand, Yvette C Cozier · 2017 to 2026
$24.0M
FOLLOW-UP STUDY FOR CAUSES OF ILLNESS IN BLACK WOMENR01CA058420 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 1999 to 2013
$20.7M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1985 to 2009
$18.2M
A Follow-up Study for Causes of Cancer in Black WomenUM1CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 2012 to 2017
$13.7M
Epidemiology of Ovarian Cancer in African-American WomenR01CA142081 · NCI · UNIVERSITY OF VIRGINIA · PI SCHILDKRAUT, JOELLEN M. · 2010 to 2015
$10.6M
Research Training Education CoreP60MD003424 · NIMHD · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CALHOUN, ELIZABETH ANN, FERRANS, CAROL E. · 2009 to 2013
$9.2M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
Interpretable Machine Learning to Identify Alzheimer's Disease Therapeutic TargetsR01AG061132 · NIA · UNIVERSITY OF WASHINGTON · PI LEE, SU-IN · 2019 to 2023
$2.9M
Exploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortiumR01CA207260 · NCI · UNIVERSITY OF VIRGINIA · PI ROSENBERG, LYNN, SCHILDKRAUT, JOELLEN M. · 2017 to 2020
$2.5M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
NCI NIH HHS K01 CA212056NCI NIH HHS K99 CA218681NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA058420NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA142081NCI NIH HHS R01 CA207260NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA164974NCI NIH HHS UM1 CA164974NIA NIH HHS R01 AG061132NIMHD NIH HHS P60 MD003424
6 · The paper itself

Abstract

backgroundMost studies examining post-menopausal menopausal hormone therapy (MHT) use and ovarian cancer risk have focused on White women and few have included Black women.

methodsWe evaluated MHT use and ovarian cancer risk in Black (n = 800 cases, 1783 controls) and White women (n = 2710 cases, 8556 controls), using data from the Ovarian Cancer in Women of African Ancestry consortium. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of MHT use with ovarian cancer risk, examining histotype, MHT type and duration of use.

resultsLong-term MHT use, ≥10 years, was associated with an increased ovarian cancer risk for White women (OR = 1.38, 95%CI: 1.22-1.57) and the association was consistent for Black women (OR = 1.20, 95%CI: 0.81-1.78, p

conclusionThe association between long-term MHT use and ovarian cancer risk was consistent for Black and White women.

Indexed as

Estrogen Replacement TherapyOvarian NeoplasmsEstrogensFemaleHumansLogistic ModelsMenopauseRisk FactorsEstrogens

Identifiers

PMID37865688
PMCPMC10703895
OpenAlexW4387845381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.